Literature DB >> 24837469

A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.

Diane M T Hanna1, Andrew Fellowes2, Ravikiran Vedururu2, Francoise Mechinaud1, Jordan R Hansford3.   

Abstract

Entities:  

Keywords:  JAK inhibitor; PMBCL; primary mediastinal B-cell lymphoma; refractory; tofacitinib

Mesh：

Substances：

Year:  2014        PMID： 24837469      PMCID： PMC4562548          DOI： 10.3324/haematol.2014.108142

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  The molecular pathogenesis of primary mediastinal large B-cell lymphoma.

Authors:  Christian Steidl; Randy D Gascoyne
Journal:  Blood       Date:  2011-06-23       Impact factor: 22.113

2.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

3.  Tofacitinib and other kinase inhibitors in the treatment of psoriasis.

Authors:  K Ortiz-Ibáñez; M M Alsina; C Muñoz-Santos
Journal:  Actas Dermosifiliogr       Date:  2013-04-11

4.  Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.

Authors:  Ghee Chong Koo; Soo Yong Tan; Tiffany Tang; Song Ling Poon; George E Allen; Leonard Tan; Soo Ching Chong; Whee Sze Ong; Kevin Tay; Miriam Tao; Richard Quek; Susan Loong; Kheng-Wei Yeoh; Swee Peng Yap; Kuo Ann Lee; Lay Cheng Lim; Daryl Tan; Christopher Goh; Ioana Cutcutache; Willie Yu; Cedric Chuan Young Ng; Vikneswari Rajasegaran; Hong Lee Heng; Anna Gan; Choon Kiat Ong; Steve Rozen; Patrick Tan; Bin Tean Teh; Soon Thye Lim
Journal:  Cancer Discov       Date:  2012-06-15       Impact factor: 39.397

5.  FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.

Authors:  Natalina E Elliott; Susan M Cleveland; Victor Grann; John Janik; Thomas A Waldmann; Utpal P Davé
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

6.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

Authors:  Michal Marzec; Qian Zhang; Ami Goradia; Puthiyaveettil N Raghunath; Xiaobin Liu; Michele Paessler; Hong Yi Wang; Maria Wysocka; Mangeng Cheng; Bruce A Ruggeri; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

7.  Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.

Authors:  Melanie G Cornejo; Michael G Kharas; Miriam B Werneck; Séverine Le Bras; Sandra A Moore; Brian Ball; Marie Beylot-Barry; Scott J Rodig; Jon C Aster; Benjamin H Lee; Harvey Cantor; Jean-Philippe Merlio; D Gary Gilliland; Thomas Mercher
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

Review 8.  Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.

Authors:  Brian W Dymock; Cheng Shang See
Journal:  Expert Opin Ther Pat       Date:  2013-02-01       Impact factor: 6.674

Review 9.  JAK3: a two-faced player in hematological disorders.

Authors:  Melanie G Cornejo; Titus J Boggon; Thomas Mercher
Journal:  Int J Biochem Cell Biol       Date:  2009-09-09       Impact factor: 5.085

10.  Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing.

Authors:  Olivier Harismendy; Richard B Schwab; Lei Bao; Jeff Olson; Sophie Rozenzhak; Steve K Kotsopoulos; Stephanie Pond; Brian Crain; Mark S Chee; Karen Messer; Darren R Link; Kelly A Frazer
Journal:  Genome Biol       Date:  2011-12-20       Impact factor: 13.583
View more
  4 in total

Review 1.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

2.  Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.

Authors:  Paola Rivera-Munoz; Anouchka P Laurent; Aurelie Siret; Cecile K Lopez; Cathy Ignacimouttou; Melanie G Cornejo; Olivia Bawa; Philippe Rameau; Olivier A Bernard; Philippe Dessen; Gary D Gilliland; Thomas Mercher; Sébastien Malinge
Journal:  Blood Adv       Date:  2018-07-10

3.  Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.

Authors:  Christoph Rummelt; Sivahari P Gorantla; Manja Meggendorfer; Anne Charlet; Cornelia Endres; Konstanze Döhner; Florian H Heidel; Thomas Fischer; Torsten Haferlach; Justus Duyster; Nikolas von Bubnoff
Journal:  Leukemia       Date:  2020-11-04       Impact factor: 11.528

4.  Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.

Authors:  Carmen Vicente; Claire Schwab; Michaël Broux; Ellen Geerdens; Sandrine Degryse; Sofie Demeyer; Idoya Lahortiga; Alannah Elliott; Lucy Chilton; Roberta La Starza; Cristina Mecucci; Peter Vandenberghe; Nicholas Goulden; Ajay Vora; Anthony V Moorman; Jean Soulier; Christine J Harrison; Emmanuelle Clappier; Jan Cools
Journal:  Haematologica       Date:  2015-07-23       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.